Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences finite-lived intangible assets, net ($M) ($M)
Form 10-Q / 10-K Note 9 Goodwill and Intangible Assets
Latest, Q2 2026
14,032
Period ended Jun 30, 2026
Change on a year earlier
-11.6%
15,866 in Q2 2025
History
50 quarters
Since Q1 2014
Sources
47
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Finite-lived intangible assets, net ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 14,032 | -11.6% | Form 10-Q (filed 2026-08-06) ↗ |
| Q1 2026 | Mar 31, 2026 | 14,082 | -14.5% | Form 10-Q (filed 2026-05-07) ↗ |
| Q4 2025 | Dec 31, 2025 | 14,678 | -14.0% | Form 10-Q (filed 2026-08-06) ↗ |
| Q3 2025 | Sep 30, 2025 | 15,270 | -13.5% | Form 10-Q (filed 2025-11-07) ↗ |
| Q2 2025 | Jun 30, 2025 | 15,866 | -12.8% | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2025 | Mar 31, 2025 | 16,465 | -12.4% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 17,058 | -12.0% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2024 | Sep 30, 2024 | 17,656 | -11.9% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 18,192 | -11.8% | Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2024 | Mar 31, 2024 | 18,788 | -11.5% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 19,384 | +23.7% | Form 10-K (filed 2025-02-28) ↗ |
| Q3 2023 | Sep 30, 2023 | 20,032 | +23.5% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2023 | Jun 30, 2023 | 20,630 | +23.8% | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2023 | Mar 31, 2023 | 21,228 | +24.1% | Form 10-Q (filed 2023-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 15,674 | -10.6% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2022 | Sep 30, 2022 | 16,220 | -8.8% | Form 10-Q (filed 2022-11-02) ↗ |
| Q2 2022 | Jun 30, 2022 | 16,665 | -8.5% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2022 | Mar 31, 2022 | 17,111 | -2.8% | Form 10-Q (filed 2022-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 17,535 | +8.0% | Form 10-K (filed 2023-02-22) ↗ |
| Q3 2021 | Sep 30, 2021 | 17,780 | +50.6% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 18,221 | +52.1% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 17,611 | +43.6% | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 16,236 | +29.4% | Form 10-K (filed 2022-02-23) ↗ |
| Q3 2020 | Sep 30, 2020 | 11,809 | -7.9% | Form 10-Q (filed 2020-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 11,983 | -8.6% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2020 | Mar 31, 2020 | 12,262 | -8.5% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 12,544 | -8.4% | Form 10-Q (filed 2020-05-06) ↗ |
| Q3 2019 | Sep 30, 2019 | 12,824 | -4.6% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 13,109 | -4.6% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 13,396 | -4.7% | Form 10-Q (filed 2019-05-08) ↗ |
| Q4 2018 | Dec 31, 2018 | 13,694 | -4.6% | Form 10-Q (filed 2019-11-05) ↗ |
| Q3 2018 | Sep 30, 2018 | 13,447 | +61.2% | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2018 | Jun 30, 2018 | 13,746 | +60.8% | Form 10-Q (filed 2018-08-06) ↗ |
| Q1 2018 | Mar 31, 2018 | 14,053 | +60.4% | Form 10-Q (filed 2018-05-09) ↗ |
| Q4 2017 | Dec 31, 2017 | 14,350 | +60.0% | Form 10-K (filed 2019-02-26) ↗ |
| Q3 2017 | Sep 30, 2017 | 8,342 | -9.2% | Form 10-Q (filed 2017-11-07) ↗ |
| Q2 2017 | Jun 30, 2017 | 8,551 | -9.0% | Form 10-Q (filed 2017-08-07) ↗ |
| Q1 2017 | Mar 31, 2017 | 8,761 | -8.8% | Form 10-Q (filed 2017-05-10) ↗ |
| Q4 2016 | Dec 31, 2016 | 8,971 | -8.6% | Form 10-K (filed 2018-02-27) ↗ |
| Q3 2016 | Sep 30, 2016 | 9,185 | -8.4% | Form 10-Q (filed 2016-11-07) ↗ |
| Q2 2016 | Jun 30, 2016 | 9,395 | -8.1% | Form 10-Q (filed 2016-08-05) ↗ |
| Q1 2016 | Mar 31, 2016 | 9,605 | -8.0% | Form 10-Q (filed 2016-05-06) ↗ |
| Q4 2015 | Dec 31, 2015 | 9,815 | -7.8% | Form 10-K (filed 2017-02-27) ↗ |
| Q3 2015 | Sep 30, 2015 | 10,022 | -7.8% | Form 10-Q (filed 2015-11-04) ↗ |
| Q2 2015 | Jun 30, 2015 | 10,228 | -6.4% | Form 10-Q (filed 2015-08-05) ↗ |
| Q1 2015 | Mar 31, 2015 | 10,435 | -6.2% | Form 10-Q (filed 2015-05-08) ↗ |
| Q4 2014 | Dec 31, 2014 | 10,641 | – | Form 10-K (filed 2016-02-24) ↗ |
| Q3 2014 | Sep 30, 2014 | 10,874 | – | SEC Filing ↗ |
| Q2 2014 | Jun 30, 2014 | 10,927 | – | SEC Filing ↗ |
| Q1 2014 | Mar 31, 2014 | 11,126 | – | SEC Filing ↗ |
Breakdown
What makes up finite-lived intangible assets, net ($m)
- Finite-lived intangible assets, gross ($M)32,413 · Q2 2026
- Finite-lived intangible assets — Accumulated amortization ($M)18,382 · Q2 2026
- Trodelvy (sacituzumab govitecan) intangible asset — Net carrying value ($M)7,026 · Q2 2026
- Sofosbuvir (Epclusa / Harvoni / Vosevi) intangible asset — Net carrying value ($M)1,923 · Q2 2026
- Yescarta (axicabtagene ciloleucel) intangible asset — Net carrying value ($M)3,780 · Q2 2026
- Hepcludex (bulevirtide) intangible asset — Net carrying value ($M)933 · Q2 2026
- Other finite-lived intangible assets — Net carrying value ($M)372 · Q2 2026
Cite this data
StockData. (2026). Gilead Sciences Finite-lived intangible assets, net ($M) ($M), quarterly Q1 2014–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/intang_finite_net
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.